Evidence map›Paper›PMID 41641362›Full record

ArticleGastro hep advances2026

Single-Cell Lineage Trajectory Defines Cyclin-Dependent Kinase Inhibitor-Sensitive Cells-of-Origin in Esophageal Squamous Cell Carcinoma.

Kyung-Pil Ko, Jie Zhang, Sohee Jun, Jae-Il Park

Abstract read
In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kyung-Pil KoDivision of Radiation Oncology, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jie ZhangDivision of Radiation Oncology, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sohee JunDivision of Radiation Oncology, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jae-Il ParkDivision of Radiation Oncology, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

Esophageal Squamous Cell Cancer Initiation and Immune Landscape RemodelingR01CA278971 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jae-Il Park · 2024 to 2026
$1.7M
Esophageal squamous cell cancer initiation and immune landscape remodelingK99CA286761 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KO, KYUNG PIL · 2024 to 2025
$258k
NCI NIH HHS K99 CA286761NCI NIH HHS R01 CA278971
6 · The paper itself

Abstract

Background and Aims: Understanding the cells of origin is essential for overcoming therapy resistance and improving early intervention strategies in esophageal squamous cell carcinoma (ESCC). Despite recent advances in genomic profiling, the precise cellular hierarchies and molecular programs driving ESCC initiation remain poorly defined. Methods: We utilized machine learning-based single-cell trajectory analysis on 4-nitroquinoline 1-oxide-induced murine models and genetically engineered organoids to identify cellular lineages during tumorigenesis. Combined with gene regulatory network analysis, we identified transcriptional drivers of tumor initiation and employed transcriptome-based drug repurposing to predict compounds targeting these initiating populations. Results: Our analyses revealed multiple distinct epithelial clusters that function as cellular origins of ESCC, exhibiting diverse stem and progenitor signatures. Gene regulatory network analysis of these populations indicated activation of stem/progenitor cell regulators, including CEBPβ and TFAP2A/C. Translating these findings, a transcriptome-based drug repurposing screen identified 5 chemical candidates, 4 of which are potent cyclin-dependent kinase inhibitors, aligning with the frequent loss-of-function mutations in Conclusion: This research delineates the potential cellular origins of ESCC and their key regulons, thereby pioneering a single-cell-derived therapeutic strategy that exposes vulnerabilities in tumor-initiating cells.

Indexed as

Cancer Stem CellsCDK InhibitorsEsophageal Squamous Cell CarcinomaSingle-Cell Transcriptomics

Identifiers

PMID41641362
PMCPMC12865637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.